A Lucknow resident, Pratap Chandra, has filed a complaint against Pune-based Serum Institute of India’s (SII) CEO Adar Poonawalla, health ministry’s joint secretary Luv Agarwal, Indian Council of Medical Research director Balram Bhargava, and National Health Mission director Aparna Upadhyay, claiming that he did not develop any antibody against COVID-19 after taking a...

Pune-based Serum Institute of India that manufactures ‘Covishield’—a jab against COVID-19 developed jointly by AstraZeneca and the University of Oxford—has announced that it will charge Rs 300 from the state government for each shot. Notably, the announcement comes a few days after Serum Institute chief Adar Poonawalla revealed that the shot will cost Rs 400...

Pune-based Serum Institute of India’s CEO Adar Poonawalla has urged US President Joe Biden to lift the embargo on raw material exports that are required for the manufacturing of vaccines. Notably, the Serum Institute is manufacturing the jab ‘Covishield’ jointly developed by AstraZeneca and the University of Oxford. Notably, Covishield is one of the most...

In an unfortunate development, five people lost their lives in the fire that broke out at Pune’s Serum Institute of India. Notably, the deceased were reportedly working in the under-construction building in SII premises where the fire broke at around 2.45 pm. The news was broke by SII chief Adar Poonawalla. He said, “We have...

Serum Institute of India (SII) chief Adar Poonawalla has said that the ‘Covishield’ vaccine that has been approved by the Indian drug regulator for restricted emergency use will be available at Rs 1,000 per shot in the retail market, if the government gives a nod for its private sale. Poonawalla said SII is selling the...

Serum Institute of India (SII) chief Adar Poonawalla has requested the Union government to indemnify it against litigations related to their vaccines, especially during a pandemic. He said vaccine manufacturers need to have protections against lawsuits and that they are going to propose the same to the government. Poonawalla said this while speaking at a...

At a time when the low-cost COVID-19 vaccine candidate jointly developed by AstraZeneca and Oxford University seems to raise hopes for many countries including India, experts have raised questions on the manner in which the company arrived at the efficacy percentage for its vaccine candidate. The questions were raised after AstraZeneca and Oxford University acknowledged...

After AstraZeneca and the University of Oxford declared that their COVID-19 vaccine candidate has efficacy of upto 90 per cent with an average efficacy pegged at 70 per cent, Serum Institute of India (SII) chief Adar Poonawalla said that a minimum of 100 million doses of its vaccine ‘Covishield’ will be available by January for...